More than 13 million people are hit by stroke each year. Globally, one in four people over the age of 25 will have a stroke in their lifetime. It is the second most common single cause of death in Europe, accounting for about 1 million deaths each year and it is the number one cause of disability.
Every year, 30,000 people in Sweden suffer a stroke, 10 percent of which are caused by a cerebral hemorrhage which accounts for 50 percent of all stroke deaths. Subarachnoid hemorrhage affects mostly people in mid-life, men and women equally. Stroke causes enormous personal, social, economic, and clinical burdens worldwide. Patients surviving a stroke most often require lengthy hospital stays and rehabilitation as well as subsequent support from the communities for their daily activities. Current therapeutic treatment options are limited, and all attempts to develop efficient drugs have proved unsuccessful.
Despite tremendous research efforts and a large number of clinical trials focused on developing treatments for stroke, the field’s current state remains dismal. There are, at present, no efficient treatments nor promising drug candidates for this lethal and disabling condition.
A different perspective with a new approach is therefore desperately needed. Edvince’s drug discovery and development is born out of founder and Professor Lars Edvinsson’s extensive, fundamental and pioneering research of cerebral circulation, receptor regulation, stroke and migraines.
Edvince is now ready to start the first clinical trial in 2021 with its innovative and disruptive lead drug EDV2209, an orphan drug for the treatment of brain ischemia associated with severe subarachnoid hemorrhage (SAH). The drug helps to keep the blood vessels in the brain open, allowing brain cells to receive oxygen and nutrients to prevent brain damage.